TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06852820: 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

Sponsor: Melissa Lumish · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06852820 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06852820 Rescue Dossier →